Amgen (AMGN), AstraZeneca (AZN) to Jointly Develop, Commercialize Clinical-Stage Inflammation Portfolio
Go back to Amgen (AMGN), AstraZeneca (AZN) to Jointly Develop, Commercialize Clinical-Stage Inflammation Portfolio| Amgen Inc (NASDAQ: AMGN) | Delayed: 439.33 +5.60 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $433.73 | 52 Week High | $176.85 | |||
| Open | $431.72 | 52 Week Low | $133.64 | |||
| Day High | $440.51 | P/E | 66.16 | |||
| Day Low | $429.38 | EPS | $6.64 | |||
| Volume | 2,114,678 | |||||
| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 3,179,791 | |||||
